Trials / Completed
CompletedNCT02138747
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 376 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.
Detailed description
The study consisted of two double-blind treatment periods with a wash-out period in between.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirabegron | Oral |
| DRUG | Tolterodine ER | Oral |
Timeline
- Start date
- 2014-07-24
- Primary completion
- 2015-10-29
- Completion
- 2015-11-11
- First posted
- 2014-05-15
- Last updated
- 2020-02-26
- Results posted
- 2017-02-14
Locations
30 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02138747. Inclusion in this directory is not an endorsement.